Compare CRNX & AZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNX | AZZ |
|---|---|---|
| Founded | 2008 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.4B |
| IPO Year | 2018 | 1994 |
| Metric | CRNX | AZZ |
|---|---|---|
| Price | $83.99 | $151.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 5 |
| Target Price | $76.75 | ★ $141.80 |
| AVG Volume (30 Days) | ★ 6.8M | 304.4K |
| Earning Date | 05-07-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 0.58% |
| EPS Growth | N/A | ★ 486.59 |
| EPS | N/A | ★ 1.72 |
| Revenue | $1,039,000.00 | ★ $1,061,817,000.00 |
| Revenue This Year | $720.10 | $7.03 |
| Revenue Next Year | $184.67 | $4.25 |
| P/E Ratio | ★ N/A | $86.73 |
| Revenue Growth | N/A | ★ 14.53 |
| 52 Week Low | $25.83 | $92.98 |
| 52 Week High | $84.00 | $162.20 |
| Indicator | CRNX | AZZ |
|---|---|---|
| Relative Strength Index (RSI) | 90.37 | 55.27 |
| Support Level | $43.40 | $132.06 |
| Resistance Level | $84.00 | $162.20 |
| Average True Range (ATR) | 0.19 | 4.40 |
| MACD | -1.64 | -0.04 |
| Stochastic Oscillator | 71.70 | 83.01 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
AZZ Inc is a provider of galvanizing and coil coating solutions to a broad range of end markets in North America. The company's operating segment consists of AZZ Metal Coatings, AZZ Precoat Metals, and AZZ Infrastructure Solutions. The company generates the majority of its revenue from the Precoat Metals segment, which provides coil coating application of protective and decorative coatings and related value-added downstream processing for steel and aluminum coils. Geographically, the company operates in the United States and Canada.